Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% |
|
-.--% | -.--% |
13/06 | Needham Downgrades Cara Therapeutics to Hold From Buy | MT |
13/06 | HC Wainwright Downgrades Cara Therapeutics to Neutral From Buy | MT |
Sales 2024 * | 6.41M 5.71M 536M | Sales 2025 * | 7.39M 6.58M 618M | Capitalization | 19.14M 17.02M 1.6B |
---|---|---|---|---|---|
Net income 2024 * | -72M -64.05M -6.01B | Net income 2025 * | -44M -39.14M -3.68B | EV / Sales 2024 * | 6.33 x |
Net Debt 2024 * | 21.5M 19.13M 1.8B | Net Debt 2025 * | 78.9M 70.19M 6.59B | EV / Sales 2025 * | 13.3 x |
P/E ratio 2024 * |
-0.28
x | P/E ratio 2025 * |
-0.48
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.75% |
Latest transcript on Cara Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 06/18/06 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 12/22/12 |
Scott Terrillion
CMP | Compliance Officer | 61 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 01/10/01 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 16/14/16 |
Helen Boudreau
BRD | Director/Board Member | 58 | 02/23/02 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.85% | 92.38B | |
-3.03% | 37.9B | |
-10.46% | 33.73B | |
+74.71% | 27.98B | |
-13.39% | 15.86B | |
-1.08% | 13.97B | |
-11.15% | 11.67B | |
+169.04% | 10.17B | |
-50.19% | 10.04B |
- Stock Market
- Equities
- CARA Stock
- 69C Stock